{
    "id": 21736,
    "fullName": "RNF11 - BRAF",
    "impact": "fusion",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "RNF11-BRAF results from the fusion of RNF11 and BRAF, leads to constitutive Mek and Erk phosphorylation and cytokine independent cell growth in culture (PMID: 26566875). RNF11-BRAF has been identified in non-Langerhans histiocytic neoplasms (PMID: 26566875).",
            "references": [
                {
                    "id": 5227,
                    "pubMedId": 26566875,
                    "title": "Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26566875"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 26994,
        "geneSymbol": "RNF11",
        "terms": [
            "RNF11",
            "CGI-123",
            "SID1669"
        ]
    },
    "variant": "RNF11 - BRAF",
    "createDate": "04/26/2016",
    "updateDate": "10/18/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 673,
                "geneSymbol": "BRAF",
                "terms": [
                    "BRAF",
                    "B-raf",
                    "B-RAF1",
                    "BRAF1",
                    "NS7",
                    "RAFB1"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 6023,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing RNF11-BRAF were insensitive to Nexavar (sorafenib)-mediated growth inhibition in culture (PMID: 26566875).",
            "molecularProfile": {
                "id": 22278,
                "profileName": "RNF11 - BRAF"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5227,
                    "pubMedId": 26566875,
                    "title": "Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26566875"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6024,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing RNF11-BRAF were sensitive to Cotellic (cobimetinib)-mediated growth inhibition in culture (PMID: 26566875).",
            "molecularProfile": {
                "id": 22278,
                "profileName": "RNF11 - BRAF"
            },
            "therapy": {
                "id": 1004,
                "therapyName": "Cobimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5227,
                    "pubMedId": 26566875,
                    "title": "Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26566875"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6022,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing RNF11-BRAF were insensitive to Zelboraf (vemurafenib)-mediated growth inhibition in culture (PMID: 26566875).",
            "molecularProfile": {
                "id": 22278,
                "profileName": "RNF11 - BRAF"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5227,
                    "pubMedId": 26566875,
                    "title": "Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26566875"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 22278,
            "profileName": "RNF11 - BRAF",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}